Histamine receptors and cancer pharmacology: an update.

Noelia A Massari, Melisa B Nicoud, Vanina A Medina
Author Information
  1. Noelia A Massari: Department of Immunology, School of Natural and Health Sciences, National University of Patagonia San Juan Bosco, Comodoro Rivadavia, Argentina.
  2. Melisa B Nicoud: Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
  3. Vanina A Medina: Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina. ORCID

Abstract

In the present review, we will discuss the recent advances in the understanding of the role of histamine and histamine receptors in cancer biology. The controversial role of the histaminergic system in different neoplasias including gastric, colorectal, oesophageal, oral, pancreatic, liver, lung, skin, blood and breast cancers will be reviewed. The expression of histamine receptor subtypes, with special emphasis on the histamine H receptor, in different cell lines and human tumours, the signal transduction pathways and the associated biological responses as well as the in vivo treatment of experimental tumours with pharmacological ligands will be described. The presented evidence demonstrates that histamine regulates cancer-associated biological processes during cancer development in multiple cell types, including neoplastic cells and cells in the tumour micro-environment. The outcome will depend on tumour cell type, the level of expression of histamine receptors, signal transduction associated with these receptors, tumour micro-environment and histamine metabolism, reinforcing the complexity of cancer disease. Findings show the pivotal role of H receptors in the development and progression of many types of cancers, and considering its immunomodulatory properties, the H receptor appears to be the most promising molecular therapeutic target for cancer treatment within the histamine receptor family. Furthermore, the H receptor is differentially expressed in tumours compared with normal tissues, and in most cancer types in which data are available, H receptor expression is associated with clinicopathological characteristics, suggesting that H receptors might represent a novel cancer biomarker. LINKED ARTICLES: This article is part of a themed section on New Uses for 21st Century. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.3/issuetoc.

References

  1. Br J Pharmacol. 2017 Dec;174 Suppl 1:S208-S224 [PMID: 29055032]
  2. Cancer Immunol Immunother. 2017 Nov;66(11):1473-1484 [PMID: 28721449]
  3. Lancet Neurol. 2013 Nov;12(11):1068-75 [PMID: 24107292]
  4. Inflamm Res. 2004 Mar;53 Suppl 1:S65-6 [PMID: 15054622]
  5. J Int Adv Otol. 2015 Aug;11(2):138-42 [PMID: 26381004]
  6. Br J Dermatol. 2017 May;176(5):1213-1223 [PMID: 27542662]
  7. Lancet Neurol. 2017 Mar;16(3):200-207 [PMID: 28129985]
  8. Oncol Rep. 2010 Mar;23(3):693-700 [PMID: 20127008]
  9. Cytokine Growth Factor Rev. 2004 Oct;15(5):393-410 [PMID: 15450254]
  10. J Cell Physiol. 2015 Nov;230(11):2626-33 [PMID: 25899612]
  11. J Gastroenterol Hepatol. 2007 Mar;22(3):436-43 [PMID: 17295779]
  12. Allergol Int. 2014 Dec;63(4):533-42 [PMID: 25249063]
  13. Gene. 2013 May 1;519(2):260-5 [PMID: 23481304]
  14. Inflamm Allergy Drug Targets. 2010 Jul;9(3):146-57 [PMID: 20632959]
  15. J Surg Res. 2005 Dec;129(2):172-5 [PMID: 15882879]
  16. EBioMedicine. 2016 Jul;9:130-139 [PMID: 27333030]
  17. Oncotarget. 2017 Apr 18;8(16):26471-26491 [PMID: 28460440]
  18. J Biol Chem. 2011 Mar 4;286(9):6979-88 [PMID: 21205825]
  19. Biochem Biophys Res Commun. 2014 Sep 5;451(4):580-6 [PMID: 25124665]
  20. Br J Cancer. 1983 Mar;47(3):367-72 [PMID: 6830687]
  21. BMC Cancer. 2015 Mar 17;15:134 [PMID: 25886177]
  22. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 25;780(2):331-9 [PMID: 12401359]
  23. Agents Actions. 1988 Apr;23(3-4):357-60 [PMID: 3394588]
  24. Int J Cancer. 2015 Mar 1;136(5):E359-86 [PMID: 25220842]
  25. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [PMID: 12917485]
  26. Int J Biochem Cell Biol. 2014 Jun;51:29-38 [PMID: 24685678]
  27. Immunol Rev. 2018 Mar;282(1):8-34 [PMID: 29431214]
  28. Life Sci. 1983 Aug 1;33(5):415-23 [PMID: 6192308]
  29. Radiat Oncol. 2010 Feb 03;5:8 [PMID: 20128919]
  30. Cell Oncol (Dordr). 2017 Dec;40(6):621-630 [PMID: 28653289]
  31. J Pharmacol Sci. 2003 Nov;93(3):321-30 [PMID: 14646250]
  32. Epilepsy Behav. 2013 Jul;28(1):66-70 [PMID: 23665640]
  33. Indian J Cancer. 2005 Oct-Dec;42(4):185-90 [PMID: 16391436]
  34. Cell Death Discov. 2015 Dec 21;1:15059 [PMID: 27551485]
  35. Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):67-72 [PMID: 18199712]
  36. Eur J Cancer Clin Oncol. 1988 Feb;24(2):161-7 [PMID: 3356203]
  37. Drugs. 2011 Jan 1;71(1):109-22 [PMID: 21175244]
  38. Cancer Lett. 1987 Feb;34(2):207-12 [PMID: 3102040]
  39. Biochem Pharmacol. 1995 Jun 29;50(1):91-6 [PMID: 7605350]
  40. Hepatology. 2011 Nov;54(5):1718-28 [PMID: 21793031]
  41. Metabolism. 2009 Jun;58(6):867-70 [PMID: 19375125]
  42. Foods. 2018 Sep 04;7(9): [PMID: 30181486]
  43. FEBS Lett. 2005 Apr 25;579(11):2475-9 [PMID: 15848191]
  44. Dig Endosc. 2012 Mar;24(2):93-9 [PMID: 22348833]
  45. Semin Cancer Biol. 2000 Feb;10(1):15-23 [PMID: 10888267]
  46. Future Oncol. 2008 Apr;4(2):169-77 [PMID: 18407731]
  47. Mol Pharmacol. 2002 Dec;62(6):1506-14 [PMID: 12435819]
  48. Nature. 2001 Apr 26;410(6832):1107-11 [PMID: 11323675]
  49. Eur J Surg Oncol. 1997 Jun;23(3):224-7 [PMID: 9236896]
  50. APMIS. 2008 Dec;116(12):1034-42 [PMID: 19133005]
  51. Cancer J. 2016 Mar-Apr;22(2):138-46 [PMID: 27111910]
  52. Cochrane Database Syst Rev. 2012 Aug 15;(8):CD007814 [PMID: 22895966]
  53. Cancer Biol Ther. 2006 Nov;5(11):1462-71 [PMID: 17012845]
  54. Carcinogenesis. 2006 Sep;27(9):1787-96 [PMID: 16569656]
  55. J Invest Dermatol. 1996 Apr;106(4):785-9 [PMID: 8618023]
  56. Front Biosci (Elite Ed). 2011 Jun 01;3(3):1042-60 [PMID: 21622113]
  57. Exp Mol Med. 2007 Jun 30;39(3):284-94 [PMID: 17603279]
  58. Inflamm Res. 2002 Jan;51(1):1-7 [PMID: 11845995]
  59. Yale J Biol Med. 1996 Jan-Feb;69(1):21-33 [PMID: 9041686]
  60. Cancer Biol Ther. 2008 Jan;7(1):28-35 [PMID: 17932461]
  61. Mol Carcinog. 2006 Jul;45(7):461-78 [PMID: 16649252]
  62. Expert Rev Mol Med. 2013 Feb 22;15:e3 [PMID: 23432971]
  63. J Rheumatol. 2016 Sep;43(9):1637-42 [PMID: 27422891]
  64. Channels (Austin). 2018 Jan 1;12(1):58-64 [PMID: 28514187]
  65. Front Immunol. 2018 Aug 15;9:1894 [PMID: 30158936]
  66. Oral Dis. 2015 Apr;21(3):378-85 [PMID: 25207698]
  67. Curr Opin Clin Nutr Metab Care. 2009 Jan;12(1):59-65 [PMID: 19057189]
  68. Melanoma Res. 2003 Jun;13(3):239-46 [PMID: 12777977]
  69. ScientificWorldJournal. 2015;2015:545292 [PMID: 25922853]
  70. Eur J Cancer. 2014 Apr;50(6):1195-206 [PMID: 24447834]
  71. Br J Pharmacol. 2020 Feb;177(3):516-538 [PMID: 30414378]
  72. Lancet Oncol. 2007 Mar;8(3):235-44 [PMID: 17329194]
  73. Cancer Lett. 2018 Jun 28;424:70-83 [PMID: 29548821]
  74. Breast. 2005 Jun;14(3):236-41 [PMID: 15927833]
  75. Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106 [PMID: 29149325]
  76. Biochem Pharmacol. 1999 Jun 15;57(12):1341-4 [PMID: 10353253]
  77. Pharmacol Rev. 1997 Sep;49(3):253-78 [PMID: 9311023]
  78. Cancer Treat Res. 2016;167:371-416 [PMID: 26601872]
  79. Cell Death Dis. 2015 Dec 31;6:e2029 [PMID: 26720338]
  80. Melanoma Res. 2011 Oct;21(5):395-404 [PMID: 21691231]
  81. Eur J Histochem. 2012 Dec 18;56(4):e48 [PMID: 23361244]
  82. Br J Pharmacol. 2017 Dec;174 Suppl 1:S1-S16 [PMID: 29055037]
  83. Cell Mol Life Sci. 2001 Feb;58(2):244-58 [PMID: 11289306]
  84. J Clin Pathol. 2001 Dec;54(12):940-4 [PMID: 11729214]
  85. Clin Oral Investig. 2013 Apr;17(3):949-55 [PMID: 22782258]
  86. Eur J Clin Invest. 2018 Oct;48(10):e13000 [PMID: 30019447]
  87. Allergy. 2016 Sep;71(9):1264-73 [PMID: 26948974]
  88. Cancer Biol Ther. 2015;16(1):137-48 [PMID: 25482934]
  89. Cancer Invest. 2000;18(4):347-55 [PMID: 10808371]
  90. Oncotarget. 2016 Mar 8;7(10):10891-904 [PMID: 26863636]
  91. Oral Dis. 2015 Sep;21(6):770-7 [PMID: 25926141]
  92. Oncol Rep. 2002 Mar-Apr;9(2):427-31 [PMID: 11836621]
  93. J Dermatol. 2015 Feb;42(2):129-39 [PMID: 25491792]
  94. World J Gastroenterol. 2014 Jul 14;20(26):8545-57 [PMID: 25024609]
  95. BMJ Open. 2011 Jul 11;1(1):e000084 [PMID: 22021756]
  96. Amino Acids. 2010 Feb;38(2):561-73 [PMID: 19997758]
  97. PLoS One. 2014 May 16;9(5):e97728 [PMID: 24835231]
  98. Anticancer Res. 2006 Jul-Aug;26(4B):2937-42 [PMID: 16886617]
  99. Eur J Cell Biol. 2008 Apr;87(4):227-36 [PMID: 18258331]
  100. Neoplasia. 2017 Aug;19(8):649-658 [PMID: 28732212]
  101. Inflamm Res. 2008;57 Suppl 1:S23-4 [PMID: 18345506]
  102. Food Chem Toxicol. 2007 Jun;45(6):935-44 [PMID: 17222494]
  103. Lung Cancer. 2012 Jan;75(1):38-44 [PMID: 21733595]
  104. Br J Pharmacol. 2017 Dec;174 Suppl 1:S272-S359 [PMID: 29055034]
  105. Mod Pathol. 2006 Jan;19(1):149-59 [PMID: 16258517]
  106. Gynecol Oncol. 2012 Oct;127(1):172-4 [PMID: 22750259]
  107. Cancer Manag Res. 2018 Feb 07;10:239-248 [PMID: 29445300]
  108. Anticancer Res. 2014 Dec;34(12):7297-301 [PMID: 25503163]
  109. Diabetes Care. 2005 Apr;28(4):940-1 [PMID: 15793203]
  110. Blood. 2011 Jun 30;117(26):7007-13 [PMID: 21518931]
  111. Front Biosci (Schol Ed). 2012 Jan 01;4(1):226-39 [PMID: 22202056]
  112. J Pharmacol Sci. 2005 Jan;97(1):116-23 [PMID: 15655289]
  113. Mol Immunol. 2013 May;54(1):74-83 [PMID: 23220070]
  114. Int J Clin Oncol. 2014 Aug;19(4):708-11 [PMID: 23828633]
  115. Cancer Res. 2008 Mar 15;68(6):1997-2005 [PMID: 18339882]
  116. World J Gastrointest Pathophysiol. 2010 Jun 15;1(2):38-49 [PMID: 21607141]
  117. Oncoimmunology. 2016 Mar 10;5(7):e1151591 [PMID: 27622015]
  118. Br J Haematol. 2009 Sep;146(6):656-9 [PMID: 19604235]
  119. Dis Colon Rectum. 2017 Sep;60(9):905-913 [PMID: 28796728]
  120. Gut. 1994 Nov;35(11):1632-6 [PMID: 7828988]
  121. Dig Dis Sci. 2008 Feb;53(2):436-42 [PMID: 17562176]
  122. J Leukoc Biol. 2017 Aug;102(2):467-474 [PMID: 28235771]
  123. Mol Cancer Res. 2009 Oct;7(10):1704-13 [PMID: 19825989]
  124. J Dermatol Sci. 2013 Dec;72(3):252-62 [PMID: 23999004]
  125. J Immunol. 2015 May 15;194(10):5014-21 [PMID: 25870245]
  126. Gut. 2012 May;61(5):753-64 [PMID: 21873469]
  127. Agents Actions. 1994 Jun;41 Spec No:C115-7 [PMID: 7976794]
  128. J Pharmacol Sci. 2007 Sep;105(1):66-73 [PMID: 17895589]
  129. J Invest Dermatol. 2001 Jul;117(1):151-3 [PMID: 11442763]
  130. Am J Pathol. 2017 Oct;187(10):2323-2336 [PMID: 28917668]
  131. Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304 [PMID: 26590477]
  132. Cancer Treat Rev. 2015 Sep;41(8):671-9 [PMID: 26145760]
  133. Pharmacol Res. 2016 Sep;111:731-739 [PMID: 27473821]
  134. PLoS One. 2012;7(2):e31207 [PMID: 22363581]
  135. Eur J Pharm Sci. 2011 Apr 18;42(5):439-44 [PMID: 21329756]
  136. Biochem Biophys Res Commun. 2001 Mar;281(5):1113-9 [PMID: 11243850]
  137. Eur J Clin Invest. 2002 Oct;32(10):743-9 [PMID: 12406022]
  138. Br J Pharmacol. 2010 Oct;161(4):755-67 [PMID: 20636392]
  139. Acta Biochim Biophys Sin (Shanghai). 2008 Mar;40(3):235-43 [PMID: 18330478]
  140. Nat Med. 2011 Jan;17(1):87-95 [PMID: 21170045]
  141. Pathol Oncol Res. 2013 Apr;19(2):311-6 [PMID: 23239191]
  142. Clin Sci (Lond). 1994 Aug;87(2):151-63 [PMID: 7924160]
  143. Pol Merkur Lekarski. 2006 Mar;20(117):318-21 [PMID: 16780265]
  144. Onco Targets Ther. 2011;4:137-48 [PMID: 21949607]
  145. Pathol Int. 2004 Jun;54(6):408-12 [PMID: 15144399]
  146. Cancer Res. 2005 May 15;65(10):4458-66 [PMID: 15899839]
  147. Semin Cancer Biol. 2019 Apr;55:78-89 [PMID: 29716829]
  148. Br J Pharmacol. 2013 Sep;170(1):188-99 [PMID: 23425150]
  149. Oncol Rep. 2016 Dec;36(6):3465-3471 [PMID: 27779705]
  150. Biomed Pharmacother. 2005 Jan-Feb;59(1-2):56-60 [PMID: 15740937]
  151. Int J Biochem Cell Biol. 2012 Dec;44(12):2124-8 [PMID: 22975449]
  152. Biochim Biophys Acta Mol Basis Dis. 2017 Nov;1863(11):2954-2963 [PMID: 28847511]
  153. Crit Rev Biochem Mol Biol. 2003;38(1):23-59 [PMID: 12641342]
  154. Expert Rev Hematol. 2010 Aug;3(4):381-91 [PMID: 21083028]
  155. Cancer Prev Res (Phila). 2014 Dec;7(12):1258-69 [PMID: 25468899]
  156. Agents Actions. 1977 Jul;7(2):209-13 [PMID: 899973]
  157. J Pharmacol Exp Ther. 2008 Aug;326(2):406-13 [PMID: 18474684]
  158. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6807-15 [PMID: 16203768]
  159. Int J Oncol. 2012 Aug;41(2):497-503 [PMID: 22615049]
  160. Pharmacol Rev. 2015 Jul;67(3):601-55 [PMID: 26084539]
  161. Cancer Immunol Res. 2017 Sep;5(9):804-811 [PMID: 28760732]
  162. Biochem Biophys Res Commun. 2016 Nov 18;480(3):479-485 [PMID: 27773822]
  163. Cell Mol Life Sci. 2004 Jan;61(1):118-28 [PMID: 14704859]
  164. Clin Ther. 2015 Oct 1;37(10):2352-64 [PMID: 26276501]
  165. Cancer Invest. 2011 May;29(4):293-9 [PMID: 21469978]
  166. Ann Allergy Asthma Immunol. 2018 Nov;121(5):568-574 [PMID: 30102965]
  167. J Immunol Res. 2018 Feb 5;2018:2584243 [PMID: 29651440]
  168. Cancer Microenviron. 2015 Dec;8(3):167-76 [PMID: 25194694]
  169. Cancer Chemother Pharmacol. 2011 Aug;68(2):359-69 [PMID: 20978762]
  170. Cancers (Basel). 2016 Feb 20;8(2): [PMID: 26907350]
  171. World J Gastroenterol. 2013 Apr 28;19(16):2560-8 [PMID: 23674860]
  172. Biochem J. 2016 Oct 1;473(19):2937-53 [PMID: 27679855]
  173. Int J Immunopharmacol. 1996 Jun-Jul;18(6-7):393-9 [PMID: 9024941]
  174. Crit Rev Oncol Hematol. 2016 Mar;99:362-75 [PMID: 26829895]
  175. FEBS Lett. 2000 May 19;473(3):345-8 [PMID: 10818238]
  176. Cancer Lett. 2016 Mar 1;372(1):89-100 [PMID: 26739061]
  177. Int J Radiat Biol. 2010 Apr;86(4):283-90 [PMID: 20353338]
  178. Br J Cancer. 2000 Jan;82(1):167-70 [PMID: 10638985]
  179. J Mol Med (Berl). 2018 Sep;96(9):951-964 [PMID: 30058054]
  180. Int J Radiat Biol. 2011 Mar;87(3):284-92 [PMID: 21142703]
  181. Methods Mol Biol. 2011;720:3-35 [PMID: 21318864]
  182. Clin Cancer Res. 2005 Jan 1;11(1):290-7 [PMID: 15671558]
  183. Br J Surg. 2002 Nov;89(11):1416-22 [PMID: 12390384]
  184. Br J Pharmacol. 2017 Dec;174 Suppl 1:S17-S129 [PMID: 29055040]
  185. CA Cancer J Clin. 2015 Mar;65(2):87-108 [PMID: 25651787]
  186. Inflamm Res. 1995 Apr;44 Suppl 1:S86-7 [PMID: 8521017]
  187. Int J Radiat Biol. 2007 Oct;83(10):653-63 [PMID: 17729160]
  188. Inflamm Res. 2011 Jan;60(1):55-61 [PMID: 20640870]
  189. Prim Care. 2015 Dec;42(4):645-59 [PMID: 26612377]
  190. Arthritis Rheum. 1995 Jan;38(1):44-8 [PMID: 7818570]
  191. Facial Plast Surg Clin North Am. 2013 Feb;21(1):33-42 [PMID: 23369587]
  192. Haematologica. 2012 Dec;97(12):1904-8 [PMID: 22689678]
  193. Hepatology. 2008 Jul;48(1):308-21 [PMID: 18536057]
  194. Amino Acids. 2014 Mar;46(3):521-30 [PMID: 23933909]
  195. Transl Gastrointest Cancer. 2012 Oct;1(3):215-227 [PMID: 24639917]
  196. J Cell Mol Med. 2003 Apr-Jun;7(2):113-26 [PMID: 12927050]
  197. Biochim Biophys Acta. 2012 Jan;1822(1):2-8 [PMID: 21130163]
  198. J Invest Dermatol. 2000 Sep;115(3):345-52 [PMID: 10951267]
  199. Life Sci. 2017 Mar 1;172:27-41 [PMID: 27986539]
  200. Clin Nutr. 2014 Feb;33(1):14-22 [PMID: 24144912]
  201. BMC Cancer. 2011 May 24;11:195:1-11 [PMID: 21609450]
  202. Onco Targets Ther. 2017 Dec 06;10:5795-5803 [PMID: 29263676]
  203. Front Oncol. 2018 Jun 18;8:218 [PMID: 29967760]
  204. Int J Oncol. 2014 Nov;45(5):1802-12 [PMID: 25119812]
  205. Int J Womens Health. 2012;4:511-20 [PMID: 23071421]
  206. J Clin Med. 2015 Apr 21;4(4):741-55 [PMID: 26239353]
  207. Blood. 2006 Jul 1;108(1):88-96 [PMID: 16556892]
  208. Br J Pharmacol. 2017 Dec;174 Suppl 1:S225-S271 [PMID: 29055036]
  209. Gen Thorac Cardiovasc Surg. 2013 Jun;61(6):330-5 [PMID: 23568356]
  210. Inflamm Res. 1995 Apr;44 Suppl 1:S68-9 [PMID: 8521007]
  211. Front Biosci (Schol Ed). 2011 Jun 01;3(3):985-94 [PMID: 21622248]
  212. Photodiagnosis Photodyn Ther. 2013 Feb;10(1):79-86 [PMID: 23465376]
  213. Br J Cancer. 2019 Jan;120(1):128-138 [PMID: 29988113]
  214. Br J Pharmacol. 2015 Mar;172(5):1165-78 [PMID: 25363289]

Grants

  1. CYTUNPSJB 80020170200043UP/Agencia Nacional de Promoción Científica y Tecnológica
  2. PICT 2015-0863/Agencia Nacional de Promoción Científica y Tecnológica
  3. /Instituto Nacional del Cáncer

MeSH Term

Breast Neoplasms
Female
Histamine
Humans
Ligands
Receptors, G-Protein-Coupled
Receptors, Histamine
Receptors, Histamine H4
Signal Transduction
Tumor Microenvironment

Chemicals

Ligands
Receptors, G-Protein-Coupled
Receptors, Histamine
Receptors, Histamine H4
Histamine

Word Cloud

Created with Highcharts 10.0.0histaminecancerreceptorsreceptorHwillroleexpressioncelltumoursassociatedtypestumourdifferentincludingcancerssignaltransductionbiologicaltreatmentdevelopmentcellsmicro-environmentsectionpresentreviewdiscussrecentadvancesunderstandingbiologycontroversialhistaminergicsystemneoplasiasgastriccolorectaloesophagealoralpancreaticliverlungskinbloodbreastreviewedsubtypesspecialemphasislineshumanpathwaysresponseswellvivoexperimentalpharmacologicalligandsdescribedpresentedevidencedemonstratesregulatescancer-associatedprocessesmultipleneoplasticoutcomedependtypelevelmetabolismreinforcingcomplexitydiseaseFindingsshowpivotalprogressionmanyconsideringimmunomodulatorypropertiesappearspromisingmoleculartherapeutictargetwithinfamilyFurthermoredifferentiallyexpressedcomparednormaltissuesdataavailableclinicopathologicalcharacteristicssuggestingmightrepresentnovelbiomarkerLINKEDARTICLES:articlepartthemedNewUses21stCenturyviewarticlesvisithttp://onlinelibrarywileycom/doi/101111/bphv1773/issuetocHistaminepharmacology:update

Similar Articles

Cited By (61)